| 张捷,毛乾泰,艾超.度拉糖肽注射液不良反应12 例文献分析[J].安徽医药,2023,27(3):633-636. |
| 度拉糖肽注射液不良反应12 例文献分析 |
| Literature analysis of 12 cases of adverse drug reactions induced by dulaglutide injection |
| |
| DOI：10.3969/j.issn.1009-6469.2023.03.047 |
| 中文关键词: 度拉糖肽 糖尿病，2型 不良反应 综述文献(主题) |
| 英文关键词: Dulaglutide Diabetes mellitus, type 2 Adverse drug reaction Review literature as topic |
| 基金项目: |
|
| 摘要点击次数: 762 |
| 全文下载次数: 210 |
| 中文摘要: |
| 目的 分析度拉糖肽注射液临床应用中药物不良反应(adverse drug reaction，ADR)的发生情况及相关因素，为临床安全用药提供参考。方法 检索CNKI中国知网、维普中文期刊服务平台、万方数据知识服务平台、PubMed、ElsevierScienceDirect全文库等建库以来至2022年2月收录的度拉糖肽注射液致ADR的个案报道，进行分析。结果 收集度拉糖肽注射液致ADR的案例报道12篇，全部为国外病例，共12例。其中男性7例(58.33%)，女性5例(41.67%)；原患疾病均为2型糖尿病，或伴有高血压、高脂血症等其他疾病；ADR主要累皮肤和软组织系统(31.58%)，其次为消化系统(26.32%)，以及心血管系统(15.79%)、泌尿系统(15.79%)、呼吸系统和神经系统(各占5.26%)；11例经停药和/或对症处理后好转，1例发生坏疽性胆囊炎导致胆囊切除。结论 度拉糖肽注射液发生ADR主要累及皮肤和软组织系统、消化系统、心血管系统、泌尿系统、呼吸系统和神经系统，发生在2个月以内居多，应加强度拉糖肽注射液用药后ADR监测，确保临床用药安全。 |
| 英文摘要: |
| Objective To analyze the occurrence and related factors of adverse drug reaction of dulaglutide injection, to provide ref?erences for clinical safe medication.Methods CNKI, VIP, Wanfang, PubMed and ElsevierScienceDirect from the establishment of the database to February 2022 were searched to retrieve information about dulaglutide injection ADR reported in the literature.Results A total of 12 cases of ADRs caused by dulaglutide injection were collected, all of which were in English. There were 7 males (58.33%)and 5 females (41.67%). The original diseases were all type 2 diabetes, or accompanied by hypertension, hyperlipidemia and other dis?eases; ADR mainly affected skin and soft tissue system (31.58%), followed by digestive system (26.32%), cardiovascular system(15.79%), urinary system (15.79%), respiratory system (5.26%) and nervous system (5.26%). Eleven cases improved after drug after withdrawal and/or symptomatic treatment, and 1 case developed gangrenous cholecystitis leading to cholecystectomy. Conclusion ADR of Duloglucoptide injection mainly involves skin and soft tissue system, digestive system, cardiovascular system, urinary system,respiratory system and nervous system, most of which occurred within 2 months, ADR monitoring of Duroc glucotide injection should be strengthened to ensure the safety of clinical medication. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
